Calgary, AB – April 3, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has agreed to settle a portion, totalling $106,200, of arrears consulting fees owed to its CEO, Nicholas Karos (the “Debt”).  UI is in process of applying to the TSX [...]